OCUL vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($96.28B market cap): the incumbent the market prices for continued execution (12.99x forward earnings, beta 0.09). OCUL is the smaller challenger ($1.25B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, OCUL fits: analysts expect its revenue to rise 78% next year, against 7% for REGN. If you believe in profit, REGN fits: it is expected to make money next year (12.99x forward earnings), while OCUL is still expected to post a loss.

OCUL vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricOCULREGNWhat it tells you
Market cap$1.25B$96.28BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-3.5612.99Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.220.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range0% of range85% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.832.79How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how OCUL and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. OCUL and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined OCUL and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ocular Therapeutix (OCUL) do?

Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Its only approved, revenue-generating product is DEXTENZA, a dexamethasone insert placed in the tear duct to treat inflammation and pain after eye surgery and, more recently, allergic eye itching. DEXTENZA generates modest sales, about $50 million over the last twelve months and slightly lower than a year ago, so the company is effectively pre-profit and funds itself with a large cash balance while it invests heavily in clinical development.

Full OCUL guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, and to about $5.12 billion in Q3 2026, up roughly 36%, taking trailing twelve-month revenue to about $16.9 billion and net income to about $4.8 billion. Quarterly net income rose from about $727 million in Q1 to about $1.3 billion in Q2 and about $1.95 billion in Q3.

Full REGN guide

OCUL vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • OCUL drivers: AXPAXLI in wet AMD; Expanding Phase 3 pipeline.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. For REGN, the clearest risk is Eylea biosimilar erosion.

OCUL or REGN: which should you pick?

If the story you believe is OCUL's (AXPAXLI in wet AMD), OCUL is the more direct way to own it; if it is REGN's (Dupixent keeps compounding), REGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the OCUL and REGN guides.

OCUL vs REGN: the full fundamentals

OCUL. Ocular is effectively a pre-profit biotech: DEXTENZA sales are small and slipped year over year in the third quarter while R&D spending funds several Phase 3 trials, keeping the net loss near $80-95 million a quarter. At ~$1.25 billion the market value sits roughly ~$800 million above net cash, so investors are pricing AXPAXLI's prospects well below the ~$1.8 billion the company was worth in May. The next report is estimated for around February 4, 2027, with consensus near a $0.35 loss per share on ~$13.7 million of revenue, and the 11 analysts Yahoo Finance tracks carry a mean target near $25.7.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last five quarters, most sharply in Q2 and Q3 2026 (about $20.07 against $16.25 in Q3), and the shares rose about 15.5% over the past month to roughly $930, up about 26% over a year. Consensus for Q4 2026 sits near $25.80 of EPS on about $5.85 billion of revenue, but 2027 EPS is forecast lower at about $62, and the ~13x forward P/E reflects the market weighing strong Dupixent growth and new launches against Eylea biosimilar erosion. After Q3, Argus lifted its target to $1,050 and Goldman Sachs to $1,115, with a 27-analyst mean near $991.

Headline figures (approximate, November 2026): OCUL shows revenue (ttm) ~$50 million, revenue (q3 2026) ~$12.9 million, down ~11.5% year over year, vs ~$13.7 million consensus, net loss (ttm) ~-$327 million (~-$1.44 per share), q3 2026 eps ~-$0.42 vs ~-$0.35 consensus; REGN shows total revenue (ttm) ~$16.9 billion, q3 2026 total revenue ~$5.12 billion (up ~36% YoY), q3 2026 eps vs estimate ~$20.07 vs ~$16.25, net income (ttm) ~$4.8 billion (~29% net margin).

The bottom line: OCUL vs REGN

OCUL and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined OCUL and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how OCUL or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ocular Therapeutix

Ask Walnut's AI anything about OCUL and see how it fits what you own.

FAQ

What is the difference between OCUL and REGN?

+

Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is OCUL or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; OCUL is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, OCUL or REGN?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both OCUL and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of OCUL vs REGN?

+

OCUL: The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting net losses of about $88.6 million in the first quarter of 2026, $78.8 million in the second and $94.8 million in the third (~$327 million over the trailing twelve months), and it may need additional capital that could dilute shareholders, especially since its runway guidance excludes the full cost of a launch. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue, which fell year over year in the third quarter, is too small to cushion a pipeline disappointment. Competition is now more concrete: Kodiak Sciences' Zenkuda posted positive one-year Phase 3 data in September 2026 with a filing planned for the same quarter as AXPAXLI's, so the two long-acting options could reach the market on similar timelines. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The market is also pricing a peak: consensus sees 2026 EPS near $69 and 2027 EPS near $62 even as revenue is forecast to rise to about $20.2 billion, so recent beats raise the bar rather than reset it, and the shares have run about 20% this year to near the top of their 52-week range. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics. Livsayis carries a boxed warning for serious meningococcal infections and a restricted REMS program, which can slow uptake of a new launch.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell OCUL or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.